International Journal of Molecular Sciences Submission Process

IJMS says manuscripts should be submitted through MDPI's system, fit the journal's molecular-sciences scope, and provide full experimental details so results can be reproduced. The instructions also state that IJMS has no maximum manuscript length if the text is concise and comprehensive.

The editorial workflow is fast but structured. MDPI describes an immediate technical pre-check, then an academic editor pre-check for scope, scientific soundness, reference relevance, and methodology. If the paper passes, it receives at least two peer reviews. Minor revisions are usually given 5 days, and major revisions are usually given 10 days.

Editorial policy states that manuscripts must fit the journal scope, be scientifically sound, and provide enough methodological detail for reproduction before the paper moves deeper into review. SciRev data reports author experiences with IJMS review speed and immediate rejection timing, which is useful context but should be treated as author-reported, not an official MDPI performance guarantee.

How this page was created: we reviewed the official IJMS homepage, MDPI instructions for authors, public issue pages, and Manusights pre-submission review notes for molecular-sciences manuscripts.

We reviewed the 100 most recent IJMS papers used. The strongest submission packages made the molecular-level contribution impossible to miss. They did not rely only on a special issue invitation, a broad disease frame, or a generic biology claim.

Manusights internal analysis identifies a failure pattern in recent manuscripts targeting IJMS: the paper may be technically formatted for MDPI, but the abstract, methods, and results do not make the molecular mechanism, reproducibility controls, or data availability concrete enough for a fast editorial pre-check. Source limitation: this is pre-submission Manusights analysis, not private MDPI editorial data.

Authors should treat IJMS speed as an editorial-screening constraint. A vague molecular mechanism, missing data path, or special-issue-first rationale can fail quickly even if the portal submission is complete.

In practice, editors specifically screen whether the molecular object, reproducible method, and data-availability path are visible before the paper leans on a disease, therapeutic, environmental, or engineering frame. A failure pattern is a manuscript that looks complete in the MDPI portal but still leaves the molecular contribution implicit until late in the Results section.

For article-pattern calibration, we checked recent IJMS publication records such as 10.3390/ijms27083538, 10.3390/ijms27010338, and 10.3390/ijms27010328. The useful pattern for authors is that accepted papers state a molecular object of study, a reproducible method, and a section or special-issue fit much earlier than weaker submissions.

The editorial office runs the Initial Quality Check first, confirming completeness and the required declarations: author contributions (authorship), competing interests, ethics approval, a plagiarism check, trial registration where applicable, and the data availability statement. After completeness is confirmed (1 to 3 days), an academic editor is assigned for editorial triage. The academic editor is a working scientist in a relevant field, not an MDPI staff member.

The academic editor checks:

• does the manuscript fit IJMS scope (molecular sciences, broadly)?

• is the methodology sound enough to justify review?

• are the claims proportional to the evidence?

• is the manuscript complete enough to send to reviewers without requesting missing basics?

Papers that clearly fall outside scope or have obvious methodological problems are returned at this stage. This is less common at IJMS than at highly selective journals, but it does happen.

Before submitting to IJMS, an IJMS submission readiness check identifies whether the package meets the editorial bar before you commit to the submission.

This guide tells you what International Journal of Molecular Sciences editors look for before reviewer assignment, and Manusights checks whether your paper passes the molecular-mechanism, reproducibility-control, data-availability, and special-issue routing tests that official MDPI guidance cannot evaluate from a generic checklist. Paid Manusights reviews are covered by a 60-day money-back guarantee, and we never train on submitted manuscripts.

Across molecular-sciences manuscripts targeting International Journal of Molecular Sciences, the strongest IJMS pages are not the ones that simply restate MDPI portal steps. They help authors decide whether the manuscript is ready for a fast academic-editor screen. IJMS is broad enough to publish molecular biology, biochemistry, molecular medicine, pharmacology, structural biology, omics, environmental molecular science, and applied molecular systems, but the common editorial bar is still molecular evidence. Across the IJMS-bound manuscripts we review, three patterns repeatedly decide whether the paper feels reviewable or merely uploadable.

Molecular mechanism hidden behind disease, therapy, or application framing

Across molecular-biology and molecular-medicine manuscripts targeting International Journal of Molecular Sciences, the most common failure mode is a paper whose abstract promises a disease, therapeutic, environmental, or engineering advance while the manuscript never makes the molecular mechanism explicit enough for an IJMS academic editor.

The figure sequence may show phenotype, viability, expression change, or material performance, but the abstract and introduction do not state the molecular question in a way that distinguishes IJMS from PLOS ONE, Scientific Reports, Cells, Cancers, Molecular Biology Reports, or Frontiers in Molecular Biosciences.

The methods may be competent, the references may be current, and the cover letter may mention a special issue, yet the editor still has to infer why the work belongs in a molecular-sciences journal rather than a broader biomedical or applied venue.

The fix starts in the manuscript components most visible at triage. The title should name the molecular axis, pathway, structure, interaction, gene set, metabolite class, or mechanistic model rather than only the clinical or application endpoint. The abstract should connect the principal result to the molecular evidence that supports it. Figure 1 should make the molecular contribution visible before secondary phenotype or performance figures.

The discussion should separate what the data show mechanistically from what the authors hope the finding may imply later. The cover letter should explain why IJMS is the right molecular-sciences venue, not just why the work is timely.

When the manuscript cannot make that case, the better redirect target may be PLOS ONE for soundness-first breadth, Scientific Reports for cross-disciplinary reporting, Cells or Cancers for cell-biology or oncology depth, or a narrower society journal where the applied endpoint is the real protagonist.

Check molecular mechanism before submitting to International Journal of Molecular Sciences →

Template-complete methods that still leave controls and data access underdeveloped

Across molecular-sciences manuscripts targeting International Journal of Molecular Sciences, a second recurring pattern is a submission that satisfies MDPI file and template expectations but still feels underdeveloped as a reproducible scientific package. IJMS can move quickly because the administrative checklist is clear, but speed does not remove the need for visible controls, raw-data access, and method detail.

The weak version has a structured manuscript, clean figure files, a data availability statement, and supplementary tables, yet the methods do not tell a reviewer enough about antibodies, cell lines, sequencing depth, compound validation, software versions, statistics, normalization choices, image acquisition, or exclusion criteria.

The data statement may say data are available on request, while the figures depend on raw blots, microscopy images, code, sequence files, or processed omics tables that are not clearly deposited.

This problem is especially visible in papers that compare IJMS with PLOS ONE, Scientific Reports, Frontiers in Molecular Biosciences, BMC Molecular and Cell Biology, or Cells as possible homes. Those venues may tolerate different narrative styles, but none of them rescue a manuscript whose controls are implied rather than documented.

For IJMS, the methods section should contain enough experimental detail for reproduction, the figure legends should name controls and sample sizes, the supplementary files should hold the extended validation rather than duplicate the main figures, and the references should support the exact assay choices rather than the broad topic.

The cover letter can help by naming the core methodological safeguards, but it cannot compensate for missing controls. A strong IJMS package makes the academic editor see that reviewer time will be spent on interpretation and significance, not on reconstructing whether the experiment was adequately controlled.

Check reproducibility before submitting to International Journal of Molecular Sciences →

Special-issue invitation stronger than the journal-fit argument

Across IJMS-targeted manuscripts, the third pattern is a paper submitted because an MDPI special-issue invitation created momentum before the authors proved that the manuscript fits International Journal of Molecular Sciences as a journal. The cover letter may name the special issue, the abstract may use the issue's topic language, and the references may cite recent IJMS articles, but the paper still reads like it was written for a narrower field journal.

Academic editors can usually separate real IJMS fit from invitation-driven routing: a genuine fit has molecular-sciences substance in the title, abstract, figures, methods, and discussion, while a weak fit depends on the special-issue label to explain why the paper is there.

The practical test is to remove the special-issue title and ask where the manuscript would belong. If the answer is still IJMS because the paper advances molecular mechanism, molecular methods, molecular pathology, molecular pharmacology, or molecular systems understanding, the submission is coherent.

If the answer becomes Cancers, Cells, Frontiers in Immunology, Frontiers in Pharmacology, Environmental Science and Pollution Research, Scientific Reports, or PLOS ONE, the manuscript probably needs either reframing or rerouting.

The manuscript components should work together: the abstract should name the molecular contribution, the figure order should build the evidence chain, the methods should support reproducibility, the data availability statement should identify concrete files or repositories, and the cover letter should explain both journal fit and issue fit. IJMS is fast, but the fastest path is not always the best path.

Authors get a cleaner editorial read when the journal-level argument is stronger than the invitation.

Check special issue routing before submitting to International Journal of Molecular Sciences →

IJMS sends papers to 2 to 3 reviewers through the MDPI Manuscript Tracking System (SuSy). IJMS uses single-blind review by default, with an optional open peer review track where authors can choose to publish the review reports alongside the article. Reviewers are asked to return reports within 10 days, which is faster than most journals.

This aggressive timeline is part of why MDPI's median first decision is about 18 days, though a slow reviewer or a major-revision round can extend that as an edge case well beyond three weeks.

Reviewers evaluate:

• scientific soundness and experimental rigor

• whether methods are described in enough detail for reproduction

• whether conclusions are supported by the data

• clarity and organization of the manuscript

• adequacy of the literature review

• Accept: the paper is ready for publication with minimal changes.

• Accept after minor revision: small changes needed (usually 5 to 10 days to revise). Changes are often verified by the academic editor without returning to reviewers.

• Major revision: substantive concerns. Typically 15 to 20 days to revise. Usually returns to the same reviewers.

• Reject and resubmit: the current version is not publishable, but a substantially revised version could be reconsidered as a new submission.

• Reject: the paper does not meet the journal's standards.

Multiple revision rounds are possible. Most papers go through 1 to 2 rounds before a final decision.

MDPI asks reviewers to respond in 10 days, but not all reviewers meet this timeline. If the process seems stalled beyond 3 weeks, you can contact the editorial office through the submission system.

Special issues often have submission deadlines. If you are close to the deadline, submit what is ready. It is better to submit on time and revise than to miss the window. But do not submit an incomplete manuscript just to meet a deadline.

IJMS covers molecular sciences broadly, but "molecular" is the operative word. A purely clinical study, a purely engineering paper, or a study without molecular-level investigation may be returned for scope mismatch.

MDPI production is strict about template compliance. If the final manuscript does not match the template, production will send it back for reformatting. Use the MDPI template from the start to avoid this delay.

• the manuscript clears template checks but the molecular-level contribution is still not obvious enough at triage

• the special-issue fit is clearer than the journal-fit argument for IJMS as a broad molecular-sciences journal

• the data-availability statement is too vague for a fast editorial read even though it is technically present

• the paper reads like a narrower field-journal draft that has not really been reframed for IJMS